Nuclear Medicine and Biology
Volume 39, Issue 1 , Pages 15-22 , January 2012

Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model

  • Anna M.E. Gustafsson

      Affiliations

    • Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 31 342 97 36.
    • ,
  • Tom Bäck

      Affiliations

    • Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • ,
  • Jörgen Elgqvist

      Affiliations

    • Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • ,
  • Lars Jacobsson

      Affiliations

    • Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • ,
  • Ragnar Hultborn

      Affiliations

    • Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • ,
  • Per Albertsson

      Affiliations

    • Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    • ,
  • Alfred Morgenstern

      Affiliations

    • European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany
    • ,
  • Frank Bruchertseifer

      Affiliations

    • European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany
    • ,
  • Holger Jensen

      Affiliations

    • PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Sture Lindegren

      Affiliations

    • Department of Radiation Physics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Received 1 April 2011 ,Revised 23 June 2011 ,Accepted 6 July 2011.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007;120:2710–2714
  3. Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH, et al. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer. 2003;13:607–613
  4. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis. Cancer Biother Radiopharm. 2000;15:53–64
  5. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm. 2001;16:305–315
  6. Mahe MA, Fumoleau P, Fabbro M, Guastalla JP, Faurous P, Chauvot P, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res. 1999;5:3249s–3253s
  7. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer. 2000;10:44–46
  8. Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 1990;8:1941–1950
  9. Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806–2811
  10. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24:571–578
  11. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32:601–614
  12. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S–204S
  13. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221–4226
  14. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907–1915
  15. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342–1350
  16. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, et al. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006;33:1065–1072
  17. Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, et al. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′)2. Int J Radiat Oncol Biol Phys. 2006;66:1228–1237
  18. Palm S, Back T, Claesson I, Danielsson A, Elgqvist J, Frost S, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69:572–579
  19. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, et al. Repeated Intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J Oncol. 2010;2010:394913
  20. Andersson H, Palm S, Lindegren S, Back T, Jacobsson L, Leser G, et al. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res. 2001;21:409–412
  21. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Anticancer Res. 2000;20:459–462
  22. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2—a phase I study. J Nucl Med. 2009;50:1153–1160
  23. http://physics.nist.gov.
  24. Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, et al. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med. 2005;46:464–471
  25. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6288–6291
  26. Morgenstern A, Zielinska B, Apostolidis C, Bruchertseifer F. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solvent Extr Ion Exc. 2007;25:339–349
  27. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166–176
  28. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157–160
  29. Mattes MJ, Look K, Furukawa K, Pierce VK, Old LJ, Lewis JL, et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res. 1987;47:6741–6750
  30. Mattes MJ, Lloyd KO, Lewis JL. Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells. Cancer Immunol Immunother. 1989;28:199–207
  31. Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3
  32. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992;3:342–345
  33. Lindegren S, Frost S, Back T, Haglund E, Elgqvist J, Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med. 2008;49:1537–1545
  34. Friesen C, Roscher M, Morgenstern A, Bruchertseifer F, Abbas K, Apostolidis C, et al. Specific activity of anti-Cd33 antibodies radiolabeled with thorium-226 or bismuth-213 plays a critical role in efficient killing of leukemia cells during radioimmunotherapy. Haematol-Hematol J. 2009;94:331–332
  35. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218–225
  36. Mirzadeh S, Kumar K, Gansow OA. The chemical fate of Bi-212-Dota formed by beta-decay of Pb-212(Dota)2-. Radiochimica Acta. 1993;60:1–10

☆ This work was carried out with research grants from the Swedish Cancer Society (grant no. 3548), the Swedish Research Council (grant no. K2007-53X-20321-01-3) and the King Gustaf V Jubilee Clinic Research Foundation in Gothenburg, Sweden.

PII: S0969-8051(11)00162-4

doi: 10.1016/j.nucmedbio.2011.07.003

Nuclear Medicine and Biology
Volume 39, Issue 1 , Pages 15-22 , January 2012

Article Tools

* Image Usage & Resolution